Last reviewed · How we verify

Diazepam Injectable Solution

Centro Medico Nacional La Raza, IMSS · FDA-approved active Small molecule

Diazepam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability.

Diazepam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability. Used for Acute seizures and status epilepticus, Acute anxiety and agitation, Muscle spasms and spasticity.

At a glance

Generic nameDiazepam Injectable Solution
SponsorCentro Medico Nacional La Raza, IMSS
Drug classBenzodiazepine
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaNeurology, Psychiatry, Critical Care
PhaseFDA-approved

Mechanism of action

Diazepam is a benzodiazepine that binds allosterically to GABA-A receptors, potentiating the effect of the inhibitory neurotransmitter GABA. This results in increased chloride ion influx into neurons, leading to hyperpolarization and reduced firing. The injectable formulation provides rapid onset for acute management of seizures, muscle spasms, and anxiety.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: